NO833976L - Fremgangsmaate ved fremstilling av steroidforbindelser med snevert partikkelstoerrelseomraade - Google Patents
Fremgangsmaate ved fremstilling av steroidforbindelser med snevert partikkelstoerrelseomraadeInfo
- Publication number
- NO833976L NO833976L NO833976A NO833976A NO833976L NO 833976 L NO833976 L NO 833976L NO 833976 A NO833976 A NO 833976A NO 833976 A NO833976 A NO 833976A NO 833976 L NO833976 L NO 833976L
- Authority
- NO
- Norway
- Prior art keywords
- particle size
- hydrogen
- particles
- methyl
- compound
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 75
- -1 STEROID COMPOUNDS Chemical class 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims description 27
- 238000002360 preparation method Methods 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 abstract description 32
- 229960001670 trilostane Drugs 0.000 abstract description 30
- 238000001727 in vivo Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 2
- 238000009826 distribution Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 5
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 229960002478 aldosterone Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 5
- 102100028255 Renin Human genes 0.000 description 4
- 108090000783 Renin Proteins 0.000 description 4
- 208000016998 Conn syndrome Diseases 0.000 description 3
- 206010020571 Hyperaldosteronism Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000013846 primary aldosteronism Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000010422 painting Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000010951 particle size reduction Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000004015 abortifacient agent Substances 0.000 description 1
- 231100000641 abortifacient agent Toxicity 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8231278 | 1982-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO833976L true NO833976L (no) | 1984-05-03 |
Family
ID=10533991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO833976A NO833976L (no) | 1982-11-02 | 1983-11-01 | Fremgangsmaate ved fremstilling av steroidforbindelser med snevert partikkelstoerrelseomraade |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0108606B1 (de) |
| JP (1) | JPS5995300A (de) |
| AT (1) | ATE38236T1 (de) |
| DE (1) | DE3378318D1 (de) |
| DK (1) | DK499683A (de) |
| ES (1) | ES8504486A1 (de) |
| FI (1) | FI834025A (de) |
| GB (1) | GB2130588B (de) |
| GR (1) | GR79688B (de) |
| IE (1) | IE56205B1 (de) |
| NO (1) | NO833976L (de) |
| PT (1) | PT77593B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8328929D0 (en) * | 1983-10-29 | 1983-11-30 | Sterwin Ag | Steroid compounds |
| US6458811B1 (en) | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
| GB2345851B (en) * | 2000-01-18 | 2004-05-26 | Gavin Paul Vinson | A combination of trilostane or keto-trilostane and an anti-oestrogen for the treatment of an oestrogen-dependent cancer or tumour |
| GB2375958B (en) * | 2001-04-09 | 2005-03-02 | George Margetts | The use of steroids to lower the levels of cortisol |
| GB2400554B (en) * | 2003-04-16 | 2007-04-18 | George Margetts | Treatment of angiotensin II-induced cardiovascular disease |
| PT1919290E (pt) | 2005-07-12 | 2014-03-20 | Ampio Pharmaceuticals Inc | Métodos e produtos para tratamento de doenças |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1123770A (en) * | 1966-11-15 | 1968-08-14 | Sterling Drug Inc | 2-cyano-3-oxo-steroids |
| US3296255A (en) * | 1963-11-29 | 1967-01-03 | Sterling Drug Inc | 2-cyano steroids |
| FR2408345A1 (fr) * | 1976-11-30 | 1979-06-08 | Besins Jean Louis | Nouvelle composition a action anti-conceptionnelle |
| US4062954A (en) * | 1976-12-27 | 1977-12-13 | Sterling Drug Inc. | Process for using a steroid compound |
| US4160027A (en) * | 1977-12-20 | 1979-07-03 | Sterling Drug Inc. | Steroid cyanoketones and intermediates |
| GB8328929D0 (en) | 1983-10-29 | 1983-11-30 | Sterwin Ag | Steroid compounds |
-
1983
- 1983-10-28 ES ES526874A patent/ES8504486A1/es not_active Expired
- 1983-10-28 JP JP58202482A patent/JPS5995300A/ja active Granted
- 1983-11-01 DK DK499683A patent/DK499683A/da not_active Application Discontinuation
- 1983-11-01 NO NO833976A patent/NO833976L/no unknown
- 1983-11-01 GB GB08329173A patent/GB2130588B/en not_active Expired
- 1983-11-02 DE DE8383306665T patent/DE3378318D1/de not_active Expired
- 1983-11-02 FI FI834025A patent/FI834025A/fi not_active Application Discontinuation
- 1983-11-02 IE IE2563/83A patent/IE56205B1/en not_active IP Right Cessation
- 1983-11-02 EP EP83306665A patent/EP0108606B1/de not_active Expired
- 1983-11-02 GR GR72848A patent/GR79688B/el unknown
- 1983-11-02 AT AT83306665T patent/ATE38236T1/de not_active IP Right Cessation
- 1983-11-02 PT PT77593A patent/PT77593B/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IE832563L (en) | 1984-05-02 |
| DE3378318D1 (en) | 1988-12-01 |
| DK499683D0 (da) | 1983-11-01 |
| DK499683A (da) | 1984-05-03 |
| EP0108606A1 (de) | 1984-05-16 |
| JPS5995300A (ja) | 1984-06-01 |
| PT77593B (en) | 1986-03-18 |
| PT77593A (en) | 1983-12-01 |
| FI834025A (fi) | 1984-05-03 |
| ES526874A0 (es) | 1985-05-01 |
| ATE38236T1 (de) | 1988-11-15 |
| GR79688B (de) | 1984-10-31 |
| IE56205B1 (en) | 1991-05-22 |
| GB2130588A (en) | 1984-06-06 |
| GB8329173D0 (en) | 1983-12-07 |
| EP0108606B1 (de) | 1988-10-26 |
| ES8504486A1 (es) | 1985-05-01 |
| FI834025A0 (fi) | 1983-11-02 |
| GB2130588B (en) | 1986-08-13 |
| JPH0443078B2 (de) | 1992-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4187423B2 (ja) | ジプラシドン組成物 | |
| US11666567B2 (en) | Bromocriptine formulations | |
| NO324037B1 (no) | Pulver for anvendelse i en torrpulverinhalator og fremgangsmate for fremstilling av pulveret | |
| NO166918B (no) | Fremgangsmaate for fremstilling av et farmasoeytisk preparat i enhetsdoseform. | |
| Yamamura et al. | Effects of automated external lubrication on tablet properties and the stability of eprazinone hydrochloride | |
| JP2013516394A (ja) | 医薬用途用の１−（１ｈ−１，２，４−トリアゾール−１−イル）ブタン−２−オール誘導体、および前記１−（１ｈ−１，２，４−トリアゾール−１−イル）ブタン−２−オール誘導体を調製するための、実質的に不定の結晶形状を有する１−（１ｈ−１，２，４−トリアゾール−１−イル）ブタン−２−オール誘導体の使用 | |
| EP1492500B1 (de) | Formoterol und ciclesonid aerosol-formulierungen | |
| NO833976L (no) | Fremgangsmaate ved fremstilling av steroidforbindelser med snevert partikkelstoerrelseomraade | |
| Li et al. | Formulation of nimodipine nanocrystals for oral administration | |
| UA57596C2 (uk) | Похідне бензотіофену, фармацевтична лікарська форма, фармацевтична композиція, спосіб лікування остеопорозу та спосіб зниження рівнів ліпідів | |
| CN108066312B (zh) | 一种帕博西尼药物组合物及其制备方法 | |
| CN105726477A (zh) | 一种小儿多潘立酮混悬液及其制备方法 | |
| de Villiers et al. | The measurement of mixture homogeneity and dissolution to predict the degree of drug agglomerate breakdown achieved through powder mixing | |
| Tinke et al. | Laser diffraction and image analysis as a supportive analytical tool in the pharmaceutical development of immediate release direct compression formulations | |
| JP2576927B2 (ja) | 細粒核 | |
| CN112741819A (zh) | 一种盐酸氟西汀胶囊及其制备方法 | |
| CN103655492A (zh) | 一种索法酮滴丸剂及其制备方法和应用 | |
| Jadhav et al. | Liquisolid technique a novel approach to enhance solubility and dissolution rate: a review | |
| Sharma et al. | Formulation, evaluation and optimization of mouth dissolving tablets of losartan potassium: effect of coprocessed superdisintegrants | |
| CN104382936B (zh) | 一种磺化去氢松香酸铋的口服固体制剂及其制备方法 | |
| Jadhav Ambadas et al. | Liquisolid Technique a Novel Approach to Enhance Solubility and Dissolution Rate: A Review | |
| Thwaites | The effect of mixing time and mixer intensity on the compression properties of tablettose® | |
| CN116462678A (zh) | 一种阿昔洛韦纳米晶及其制备方法 | |
| Shrikhande et al. | Rifampicin and Isoniazid microcapsules for treatment of tuberculosis | |
| Pazesh et al. | Comminution-amorphisation relationships during ball |